Guillain-Barré syndrome (Q28273931)

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Mimics and chameleons in Guillain-Barré and Miller Fisher syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Glycolipid antigens and autoantibodies in autoimmune neuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Genetics of Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): current knowledge and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Innate Immunity to Campylobacter jejuni in Guillain-Barré Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Peripheral nerve proteins as potential autoantigens in acute and chronic inflammatory demyelinating polyneuropathies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Biomarkers in experimental models of antibody-mediated neuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Supportive care for patients with Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Intravenous immunoglobulin for Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Outcome and its predictors in Guillain-Barre syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Early recognition of poor prognosis in Guillain-Barre syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Population Incidence of Guillain-Barré Syndrome: A Systematic Review and Meta-Analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Seasonal variation in Guillain-Barré syndrome: a systematic review, meta-analysis and Oxfordshire cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

A 15-Year Nationwide Epidemiological Analysis of Guillain-Barré Syndrome in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Binational outbreak of Guillain-Barré syndrome associated with Campylobacter jejuni infection, Mexico and USA, 2011.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

The occurrence of Guillain-Barre syndrome within families

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Familial Guillain-Barré syndrome: First Indian report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

The risk of Guillain-Barré syndrome following infection with Campylobacter jejuni

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

The spectrum of antecedent infections in Guillain-Barre syndrome: A case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Campylobacter jejuni infection and Guillain-Barré syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Haemophilus influenzae infection and Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Hepatitis E and Guillain-Barre syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Guillain-Barré syndrome associated with preceding hepatitis E virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Zika virus: following the path of dengue and chikungunya?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Guillain-Barré syndrome after exposure to influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Recurrences, vaccinations and long-term symptoms in GBS and CIDP.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

The immunobiology of Guillain-Barré syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Severe axonal degeneration in acute Guillain-Barré syndrome: evidence of two different mechanisms?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Peripheral neuropathies and anti-glycolipid antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Comparative study of preceding Campylobacter jejuni infection in Guillain-Barré syndrome in Japan and The Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Animal models of autoimmune neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

The translation of the pathological findings described in humans to experimental models of acute motor axonal neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Campylobacter jejuni from patients with Guillain-Barré syndrome preferentially expresses a GD(1a)-like epitope.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Immune responses to myelin proteins in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Ranvier revisited: novel nodal antigens stimulate interest in GBS pathogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Moesin is a possible target molecule for cytomegalovirus-related Guillain-Barré syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Are ERM (ezrin/radixin/moesin) proteins targets for autoantibodies in demyelinating neuropathies?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Clinical features in Guillain-Barré syndrome with anti-Gal-C antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Ganglioside complexes as new target antigens in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Antibodies to heteromeric glycolipid complexes in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

The application of glycosphingolipid arrays to autoantibody detection in neuroimmunological disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Non-demyelinating, reversible conduction failure in Fisher syndrome and related disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

A common mechanism and a new categorization for anti-ganglioside antibody-mediated neuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Nodo-paranodopathy: beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Mechanisms of distal axonal degeneration in peripheral neuropathies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Conduction block in acute motor axonal neuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Paraparetic Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Pain in Guillain-Barre syndrome: a long-term follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Guillain–Barré syndrome associated with normal or exaggerated tendon reflexes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Subacute inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Cytoalbuminologic dissociation in Asian patients with Guillain-Barré and Miller Fisher syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Pure sensory Guillain-Barré syndrome: A case report and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Guillain-Barré syndrome in Taiwan: a clinical study of 167 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Clinical predictors of mechanical ventilation in Fisher/Guillain-Barre overlap syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Long-term outcome of Guillain-Barré syndrome in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Recognizing Guillain-Barre syndrome in preschool children.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Neurophysiologic findings in early acute inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Reversible conduction failure is distinct from neurophysiological patterns of recovery in mild demyelinating Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Electrodiagnosis of GBS subtypes by a single study: not yet the squaring of the circle

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Pharmacological treatment for pain in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Plasma exchange for Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Immunotherapy for Guillain-Barre syndrome: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Intravenously Administered Immunoglobulin in the Treatment of Childhood Guillain-Barre Syndrome: A Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

An open label clinical trial of complement inhibition in multifocal motor neuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Mortality in mechanically ventilated patients of Guillain Barré Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Guillain-Barré syndrome in Arab countries: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Mortality in Guillain-Barre syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Residual fatigue in Guillain-Barre syndrome is related to axonal loss

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Fatigue in immune-mediated neuropathies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

196th ENMC international workshop: Outcome measures in inflammatory peripheral neuropathies 8-10 February 2013, Naarden, The Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

A clinical prognostic scoring system for Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

Guillain–Barré Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900339-1

7 January 2021

10.1016/S0140-6736(16)00339-1

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

2707640

2707640

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference